First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline. Issue 3 (10th June 2016)

• Record Type: Journal Article
• Authors: Tadolini, Marina; Lingtsang, Rangjung Dolma; Tiberi, Simon; Enwerem, Martin; D'Ambrosio, Lia; Sadutshang, Tsetan Dorji; Centis, Rosella; Migliori, Giovanni Battista
• Is Part Of: European respiratory journal. Volume 48:Issue 3(2016)
• Page Start: 935
• Page End: 938
• Publication Date: 2016-06-10
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; 616.2
• DOI: 10.1183/13993003.00637-2016
• Languages: English
• ISSNs: 0903-1936

Abstract

The European Respiratory Journal has recently discussed delamanid and bedaquiline and their use in difficult-to-treat cases affected by multidrug-resistant tuberculosis (MDR-TB) or extensively drug-resistant (XDR-TB) [1–4]. The use of delamanid or bedaquiline is particularly important when four active drugs cannot be identified and included in a regimen, as per World Health Organization (WHO) guidelines [1–6]. Recently a debate has been initiated around the report of a severe, almost untreatable, XDR-TB case who could not access both new drugs simultaneously [7–10] due to concerns about possible additive toxicity (cardiotoxicity), as well as the lack of evidence and specific guidance on their combined use [10–13]. Report of the first case, concerns and challenges of treatment of severe XDR-TB with both delamanid and bedaquiline http://ow.ly/WzeB3004Cmo